Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021064152 - HYBRID ANTIBODY

Publication Number WO/2021/064152
Publication Date 08.04.2021
International Application No. PCT/EP2020/077608
International Filing Date 01.10.2020
IPC
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
C07K 16/32 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
32against translation products from oncogenes
Applicants
  • EPSILOGEN LTD [GB]/[GB]
Inventors
  • WILSON, Tim
  • FITZGERALD, Kevin
Agents
  • SCRIPT IP LIMITED
  • DEMPSTER, Robert, Charles
Priority Data
1914165.401.10.2019GB
1917059.622.11.2019GB
2008248.302.06.2020GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HYBRID ANTIBODY
(FR) ANTICORPS HYBRIDE
Abstract
(EN)
Described herein are hybrid antibodies targeted for use in the treatment of cancer. The antibodies have binding capabilities for Fcε receptors and Fcγ receptors, which may be achieved e.g. by grafting heavy chain constant domain sequences (e.g. CH2 and CH3 domains) derived from IgG to IgE.
(FR)
L'invention concerne des anticorps hybrides ciblés pour une utilisation dans le traitement du cancer. Les anticorps ont des capacités de liaison pour les récepteurs Fcε et les récepteurs Fcγ, qui peuvent être obtenues par exemple par greffage de séquences de domaines constants de chaînes lourdes (par exemple des domaines CH2 et CH3) dérivées d'IgG sur des IgE.
Latest bibliographic data on file with the International Bureau